New treatment approach for multiple myeloma using a specific enzyme inhibitor
Geranylgeranyl diphosphate synthase inhibitor therapy for multiple myeloma
This study is exploring a new treatment for multiple myeloma that targets a specific enzyme to help cancer cells die off, and if successful, it could offer hope for patients dealing with this type of bone marrow cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project ID | NIH-11047571 on NIH RePORTER |
What this research studies
This research investigates a novel therapy for multiple myeloma, a type of bone marrow cancer, by targeting an enzyme called geranylgeranyl diphosphate synthase (GGDPS). The approach involves using inhibitors that disrupt the trafficking of monoclonal proteins within cancer cells, leading to their accumulation and eventual cell death. The study includes preclinical testing in mouse models to evaluate the effectiveness and safety of these inhibitors, focusing on their ability to induce stress in cancer cells and overcome drug resistance. Patients may benefit from this innovative treatment strategy if it proves effective in clinical settings.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with multiple myeloma who have not responded adequately to existing treatments.
Not a fit: Patients with other types of cancers or those who do not have multiple myeloma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option for patients with multiple myeloma, potentially improving treatment outcomes and overcoming drug resistance.
How similar studies have performed: Preliminary studies have shown promise with similar approaches, indicating potential for success in this novel treatment strategy.
Where this research is happening
Omaha, United States
- University of Nebraska Medical Center — Omaha, United States (Active)
Researchers
- Principal investigator: Holstein, Sarah a — University of Nebraska Medical Center
- Study coordinator: Holstein, Sarah a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.